Table 2. Case enrichment in breast and prostate cancer PRS top 10% versus bottom 90%.
| GWAS Trait/Outcome | Ancestry Group | GPRS | CSPRS | ||
|---|---|---|---|---|---|
| OR Top 10% (95% CI) | P | OR Top 10% (95% CI) | P | ||
| Overall Breast Cancer | EUR | 2.36 (2.26, 2.47) | 1.0x10-328 | 2.81 (2.69, 2.93) | 2.5x10-499 |
| SAS | 2.54 (1.70, 3.79) | 5.98x10-6 | 2.33 (1.55, 3.51) | 5.01x10-5 | |
| AFR | 2.18 (1.36, 3.49) | 0.00116 | 2.88 (1.85, 4.48) | 2.75x10-6 | |
| EAS | 3.52 (1.79, 6.9) | 0.000254 | 2.60 (1.25, 5.40) | 0.0106 | |
| Prostate Cancer | EUR | 3.32 (3.13, 3.52) | 1.26x10-346 | 4.00 (3.78, 4.23) | 3.77x10-495 |
| SAS | 3.11 (1.66, 5.84) | 0.000409 | 4.41 (2.43, 8.04) | 1.18x10-6 | |
| AFR | 1.41 (0.85, 2.34) | 0.179 | 1.78 (1.09, 2.92) | 0.0223 | |
| EAS | 4.89 (1.26, 19.0) | 0.0219 | 6.53 (1.71, 25.0) | 0.00614 | |
Abbreviations: PRS, polygenic risk score; GPRS: GWAS Hits-based PRS; CSPRS: PRS-CS based PRS; AFR, African; EAS, East Asian; EUR, European, SAS, South Asian